Global glioblastoma market set to reach $1.4 billion by 2027, says analyst

12 November 2018

Although the glioblastoma (GBM) treatment market is small with many unmet needs, it is expected to grow from $662.0 million in 2017 to $1.4 billion in 2027 across the eight major markets (8MM) at a compound annual growth rate (CAGR) of 7.5%, according to data and analytics company GlobalData.

The company’s latest report: ‘ Glioblastoma Multiforme (GBM) Opportunity Analysis and Forecasts to 2027’ states that a drive to address the high level of unmet needs will be hindered by difficulties in clinical development, leading to only modest growth in the GBM market.

Ashwin Oberoi, pharma analyst at GlobalData, says: “Clinical trial design for glioblastoma is extremely challenging, many drugs have shown promise in early-stage single arm studies but end up failing in randomized Phase III trials. GBM is considered a disease with some of the highest unmet needs in oncology, where patients have a median overall survival between one and two years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK